Bronchiectasis With Acute Exacerbation, COPD Exacerbation
Conditions
Keywords
Chronic Obstructive Pulmonary Disease, Bronchiectasis
Brief summary
Chronic obstructive pulmonary disease (COPD) and bronchiectasis are common chronic respiratory diseases in China. COPD is characterized by irreversible lung function decline due to airway inflammation, emphysema and alveolar destruction. Bronchiectasis is characterized by permanent bronchiectasis, its main clinical symptoms are cough, dyspnea, hemoptysis and recurrent respiratory tract infections. The incidence and prevalence of bronchiectasis have assumed continuously grows in global. Airway microbiota, whose alterations play an important role in the occurrence and development of bronchiectasis, form a complex ecosystem interacted with host cells and various biotic and abiotic factors in the microenvironment. Additionally, mounting evidence suggests that the airway microbiome is associated with COPD phenotypes and endotypes, and that dysbiosis contributes to airway inflammation. However, the mechanisms remain poorly understood, owing to limited knowledge of microbial functional properties, metabolic activities and cross-talk with the host immune system. The investigators aim to collect sputum specimen and perform multi-omic analysis on patients with COPD and bronchiectasis in seven clinical centres in China.
Interventions
OTHERNo intervention
No intervention
Sponsors
Ruijin Hospital
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients diagnosed with bronchiectasis (according to the Chinese consensus, patient's previous chest CT examination must show bronchiectasis) or COPD (according to GOLD 2022). * Patients with age ≥18 years old. * Written informed consent.
Exclusion criteria
* Pregnancy or lactation, or those without taking effective contraceptive measures * Subjects with a history of mental illness or suicide risk, with a history of epilepsy or other central nervous system disorders * Subjects with a history of alcohol or illicit drug abuse * Subjects with any of the following pulmonary diseases: active tuberculosis, pulmonary embolism, pneumothorax, multiple huge bullae, uncontrolled asthma, acute exacerbation of chronic bronchitis or extremely severe COPD * Diagnosis of chronic gastrointestinal disease, heart disease, diabetes, severe renal insufficiency (GFR \< 30ml/min) or immunodeficiency * Participated in any interventional clinical trial within 3 months before enrolment. * Poor compliance or inability to cooperate as judged by the doctor
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change of lung microbiome in COPD and bronchiectasis patient between exacerbation and clinically stable stage | Day0 and week 10 | The lung microbiome of COPD and bronchiectasis patients will be defined from sputum samples using traditional bacterial culture and 16S rRNA sequencing. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change of lung metabolomics in COPD and bronchiectasis patient between exacerbation and clinically stable stage | Day0 and week 10 | The lung microbiome of COPD and bronchiectasis patients will be defined from sputum samples using liquid chromatography-mass spectrometry (LC-MS)-based metabolomics approach. |
| Change of lung proteomics in COPD and bronchiectasis patient between exacerbation and clinically stable stage | Day0 and week 10 | The lung microbiome of COPD and bronchiectasis patients will be defined from sputum samples using Olink multiplex panel. |
Countries
China
Contacts
Primary ContactJieming Qu
Outcome results
None listed